drugset / Trial / NCT06857747
Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the efficacy of Disitamab vedotin in combination with metronomic chemotherapy in advanced breast cancer. By integrating the rapid onset of action of Disitamab vedotin with the characteristics of metronomic chemotherapy, the study seeks to further improve patients' response rates and enhance their quality of life, building upon the extension of patient survival.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2025-12-01
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Capecitabine | Small molecule | 500 mg | — |
| Background | Etoposide | Small molecule | 50 mg | — |
| Background | Vinorelbine | Small molecule | 40 mg | — |